GlassScriptPhysician profile
Zeba Faroqui
NPI 1326426966
$13,725.96
in general payments reported to CMS, 2019-2025
41 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $440 · 2021: $3,111 · 2022: $2,303 · 2023: $2,983 · 2024: $3,022 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,677 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,677.05 |
| Education | $195.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,896.68 | 2020-2025 | Tavneos, Krystexxa, Enbrel |
| Abbvie INC. | $1,786.24 | 2020-2025 | |
| Janssen Biotech, INC. | $1,706.63 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Mallinckrodt Hospital Products INC. | $1,152.16 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $1,051.63 | 2021-2023 | Krystexxa |
| Pfizer INC. | $789.63 | 2020-2025 | |
| Lilly USA, LLC | $618.61 | 2020-2025 | Taltz, Olumiant |
| Astrazeneca Pharmaceuticals LP | $579.49 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $487.12 | 2022-2025 | Ofev, Cyltezo |
| Radius Health, INC. | $423.68 | 2020-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $416.67 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $349.31 | 2021-2025 | Benlysta |
| Scilex Pharmaceuticals INC. | $304.55 | 2024 | |
| Ucb, INC. | $235.98 | 2021-2024 | Cimzia |
| Novartis Pharmaceuticals Corporation | $218.24 | 2020-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $169.20 | 2021-2023 | Uptravi, Opsumit |
| Ferring Pharmaceuticals INC. | $130.32 | 2021-2025 | Euflexxa |
| E.R. Squibb & Sons, L.L.C. | $128.52 | 2024-2025 | Orencia, Sotyktu |
| Sobi, INC | $126.01 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $116.50 | 2025 | Tremfya |
| Depuy Synthes Sales INC. | $114.79 | 2021-2024 | Orthovisc |
| Alexion Pharmaceuticals, INC. | $111.93 | 2022-2025 | Strensiq |
| Bioventus LLC | $97.89 | 2023-2025 | Durolane, Supartz Fx Sodium Hyaluronate, Durolane |
| Genentech USA, INC. | $79.74 | 2020-2022 | |
| Genzyme Corporation | $78.62 | 2021-2023 | |
| Hikma Pharmaceuticals USA | $66.55 | 2021-2022 | |
| Octapharma USA, INC. | $51.07 | 2024-2025 | Octagam Immune Globulin (Human) |
| Aurinia Pharma U.S., INC. | $49.83 | 2023-2024 | Lupkynis |
| Kiniksa Pharmaceuticals International, Plc | $46.63 | 2024 | Arcalyst |
| Fidia Pharma USA INC. | $46.61 | 2025 | Triluron, Hymovis |
| Kiniksa Pharmaceuticals, LTD. | $46.39 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $45.04 | 2021-2022 | |
| Sandoz INC. | $34.41 | 2023-2024 | Hyrimoz |
| Janssen Scientific Affairs, LLC | $31.52 | 2021 | |
| Renalytix Ai, INC. | $24.99 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Zimmer Biomet Holdings, INC. | $24.73 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Takeda Pharmaceuticals U.S.A., INC. | $20.65 | 2020 | |
| Alnylam Pharmaceuticals INC. | $20.36 | 2023 | Amvuttra |
| Eyevance Pharmaceuticals LLC | $16.11 | 2021 | |
| Lundbeck LLC | $16.02 | 2022 | |
| Acadia Pharmaceuticals INC | $14.91 | 2025 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeba Faroqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.